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Abstract
Fungal peritonitis remains a serious complication of peritoneal dialysis that carries a high morbidity and mortality.
Most cases of fungal infections are due to Candida species; however few cases are seen in the setting of non-Candida such
Aspergillus, Fusarium, and Mucor. Prompt peritoneal dialysis catheter removal and early anti-fungal treatment have been
considered as best strategies to improve survival.
We present a rare case of a 27-year-old male with focal segmental glomerulosclerosis on peritoneal dialysis (PD)
presented to the hospital recurrent episodes of abdominal pain, diarrhea, and cloudy output from his peritoneal catheter.
He was found to have fungal peritonitis secondary to Aspergillosis Fumigatus. This report highlights that fungal peritonitis should be considered in the differential diagnosis of patients with prolonged antibiotic use, recent bacterial
peritonitis, and recent hospitalization. The speciation of Aspergillosis Fumigatus carries a rare incidence in this population
and voriconazole is the mainstay treatment.
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1. Introduction

A

cute peritonitis is a common complication of
peritoneal dialysis, oftentimes in the setting
of bacterial infection.1 Less than 10% of cases are
due to fungal infections.2 While candida species are
the most frequently cultured, other species Aspergillus, Fusarium, and Mucor - are found in
2e5% of fungal peritonitis cases.3 Fungal peritonitis
carries a high mortality rate of up to 45%.4

2. Case description
A 27-year-old male with hypertension and focal
segmental glomerulosclerosis on peritoneal dialysis
(PD) presented to the hospital 4 days after discharge
with recurrent episodes of abdominal pain, diarrhea, and cloudy output from his peritoneal
catheter.
 Prior cultures initially demonstrated Staphylococcus epidermidis for which he was treated with
intraperitoneal (IP) vancomycin and gentamicin

then he was discharged as he demonstrated
symptomatic improvement.
Unfortunately, a few days post-discharge, he
continued to have symptoms and was rehospitalized.
 Workup:
▪ Peritoneal ﬂuid count: 5000 cells/mL with
74% neutrophils.
▪ A CT scan of his abdomen was compatible
with peritonitis (Fig. 1).
 Hospital Course:
 He was resumed on IV vancomycin and his PD
catheter was removed.
 Despite IV antibiotics, he experienced increasing
abdominal pain with rising leukocytosis and
fever.
 Preliminary peritoneal culture data demonstrated the presence of mold with subsequent
speciation of Aspergillus fumigatus.
 Antibiotics were switched to voriconazole 200 mg
twice daily for a total of four weeks (Table 1).
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Fig. 1. Computed tomography of the abdomen and pelvis in coronal and axial views demonstrating the presence of signiﬁcant peritoneal ﬂuid. CT also
demonstrated evidence of marked peritoneal enhancement suggestive of ongoing inﬂammation.

 Repeat paracentesis performed on day 5 of
therapy revealed a normal cell count. (see Table
2).



3. Discussion
 PD-associated peritonitis diagnosis should be
established when at least two of the following
are present: presence of cloudy output/abdominal pain, white cell count >100/mL with >50%
polymorphonuclear cells; and positive PD aspirate culture.5 In addition, the presence of
Table 1. Aspergillus Fumigatus antifungal sensitivities taken from
peritoneal culture data. MIC (Minimum Inhibitory Concentration).
Aspergillus Fumigatus Group

MIC

Isavuconazole
Itraconazole
Posaconazole
Voriconazole
Amphotericin B
Micafungin
Caspofungin
Anidulafungin

1
0.12
0.06
0.5
1
0.06
0.06
0.06




Table 2. Abdominal ﬂuid analysis on day of presentation vs day 5 of
voriconazole treatment.
Appear peritoneal ﬂuid (PF)
Color PF
RBC PF
WBC PF
Neutrophils PF %
Lymphocyte PF %
Eosinophils PF %
Other cells PF %

Day 1

Day 5

Cloudy
Pale Yellow
Occasional
5095
74
6
9
11

Slightly Cloudy
Yellow
Moderate
147
1
66
4
29



peritoneal eosinophilia in patients on PD should
raise the suspicion towards fungi as the culprit
agent.6
Recommended empirical antibiotic therapy per
last guidelines5 should be started as soon as the
cultures have been obtained with coverage for
both Gram-positive and Gram-negative organisms. Gram-negative organisms covered by a
third-generation cephalosporin or an aminoglycoside (e.g., gentamicin) and Gram-positive
organisms covered by vancomycin or a ﬁrstgeneration cephalosporin. Unless patient has
features of future sepsis, IP antibiotics is the
preferred route of administration. Once culture
has speciated, antibiotic therapy should be
adjusted in the case of coagulase-negative
staphylococci peritonitis should be treated with
IP vancomycin or ﬁrst-generatio cephalosporins
for two weeks.7
Fungal peritonitis due to Aspergillus Fumigatus
is rare and associated with high mortality due to
diagnostic delay and delayed removal of the
indwelling PD catheter.8
Mortality increases with prolonged antibiotic
use, recent bacterial peritonitis, and recent
hospitalization.3
For PD patients who receive prolonged antibiotic therapy, prophylaxis with anti-fungal may
reduce incidence of fungal peritonitis. Recent
guidelines discussed 2 randomized controlled
trials9,10 and a systematic review11 that examined
use of either oral nystatin or ﬂuconazole as
prophylaxis during antibiotic therapy with signiﬁcant beneﬁt.5 Another retrospective cohort
study12 in patients with bacterial peritonitis

revealed there is signiﬁcant reduction of fungal
peritonitis with use of prophylactic ﬂuconazole
at a dose of 200 mg/day for 7 days.
 The mainstay treatment for Aspergillus Fumigatus fungal peritonitis is voriconazole; patients
should be treated for at least four weeks until all
symptoms and signs have resolved.13 Other
treatment modalities include intravenous and/or
IP administration of amphotericin B monotherapy in combination with ﬂuconazole, or with
itraconazole, or with caspofungin, or with ketoconazole. Per the 2016 update by the infectious
disease society of America for practice guidelines for the diagnosis and management of
Aspergillosis; amphotericin B is an appropriate
option for treatment of Aspergillosis only when
voriconazole cannot be administered.14

4. Conclusion
Fungal peritonitis carries a high mortality rate and
is often a missed complication of peritoneal dialysis.
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